Arrowhead Pharmaceuticals Inc
ARWR64.520USD
-0.120-0.19%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
8.86BMarket Cap
40.35P/E TTM
More Details of Arrowhead Pharmaceuticals Inc Company
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
Arrowhead Pharmaceuticals Inc Info
Ticker SymbolARWR
Company nameArrowhead Pharmaceuticals Inc
IPO dateDec 14, 1993
CEOAnzalone (Christopher Richard)
Number of employees711
Security typeOrdinary Share
Fiscal year-endDec 14
Address177 E Colorado Blvd
CityPASADENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91105
Phone16266964702
Websitehttps://arrowheadpharma.com/
Ticker SymbolARWR
IPO dateDec 14, 1993
CEOAnzalone (Christopher Richard)
Company Executives of Arrowhead Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-13187.00%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+23007.00%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
63.01K
+8027.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+12801.00%
Ms. Victoria (Vicki) Vakiener
Ms. Victoria (Vicki) Vakiener
Independent Director
Independent Director
35.72K
--
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Dr. Adeoye Y. (Oye) Olukotun, M.D.
Independent Director
Independent Director
33.60K
--
Mr. Vincent Anzalone
Mr. Vincent Anzalone
Investor Relations
Investor Relations
--
--
Mr. William D. Waddill
Mr. William D. Waddill
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Dr. Christopher Richard (Chris) Anzalone, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
3.79M
-13187.00%
Mr. Patrick C. O'Brien, J.D.
Mr. Patrick C. O'Brien, J.D.
Chief Operating Officer, General Counsel, Company Secretary
Chief Operating Officer, General Counsel, Company Secretary
547.41K
+23007.00%
Dr. Michael S. (Mike) Perry, Ph.D.
Dr. Michael S. (Mike) Perry, Ph.D.
Independent Director
Independent Director
123.06K
--
Dr. Mauro Ferrari, Ph.D.
Dr. Mauro Ferrari, Ph.D.
Independent Director
Independent Director
69.05K
--
Dr. Hongbo B. Lu, Ph.D.
Dr. Hongbo B. Lu, Ph.D.
Independent Director
Independent Director
63.01K
+8027.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
59.02K
+12801.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.12%
The Vanguard Group, Inc.
10.90%
Avoro Capital Advisors LLC
7.78%
State Street Investment Management (US)
4.57%
Fidelity Management & Research Company LLC
4.11%
Other
59.52%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.12%
The Vanguard Group, Inc.
10.90%
Avoro Capital Advisors LLC
7.78%
State Street Investment Management (US)
4.57%
Fidelity Management & Research Company LLC
4.11%
Other
59.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.69%
Investment Advisor/Hedge Fund
27.59%
Hedge Fund
8.16%
Individual Investor
3.80%
Research Firm
2.44%
Sovereign Wealth Fund
1.39%
Pension Fund
0.99%
Bank and Trust
0.35%
Venture Capital
0.18%
Other
13.42%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
591
114.80M
88.39%
+9.71K
2025Q3
611
114.80M
88.75%
+6.59M
2025Q2
590
107.34M
86.27%
+533.10K
2025Q1
582
106.99M
81.94%
-5.53M
2024Q4
591
101.33M
89.06%
+682.02K
2024Q3
588
101.78M
87.03%
+1.24M
2024Q2
591
100.85M
86.00%
+921.50K
2024Q1
603
99.92M
69.60%
+13.68M
2023Q4
610
81.59M
77.27%
+3.47M
2023Q3
608
78.04M
73.69%
+2.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
18.37M
13.52%
+771.04K
+4.38%
Sep 30, 2025
The Vanguard Group, Inc.
16.01M
11.79%
+510.80K
+3.30%
Sep 30, 2025
Avoro Capital Advisors LLC
10.90M
8.03%
+300.00K
+2.83%
Sep 30, 2025
State Street Investment Management (US)
6.40M
4.71%
+26.31K
+0.41%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.76M
4.24%
+589.26K
+11.40%
Sep 30, 2025
Slate Path Capital LP
4.98M
3.67%
-250.00K
-4.78%
Sep 30, 2025
Anzalone (Christopher Richard)
3.81M
2.8%
-115.33K
-2.94%
Dec 29, 2025
Geode Capital Management, L.L.C.
3.13M
2.31%
+152.54K
+5.12%
Sep 30, 2025
Invus Public Equities Advisors, LLC
2.67M
1.97%
--
--
Sep 30, 2025
Driehaus Capital Management, LLC
2.10M
1.55%
+1.49M
+244.15%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Genomics & Biotechnology ETF
5.45%
Invesco S&P SmallCap Health Care ETF
3.59%
ROBO Global Healthcare Technology & Innovation ETF
3.41%
ALPS Medical Breakthroughs ETF
2.38%
Tema Heart & Health ETF
2.18%
Invesco Dorsey Wright Healthcare Momentum ETF
1.89%
Virtus LifeSci Biotech Clinical Trials ETF
1.77%
State Street SPDR S&P Biotech ETF
1.18%
First Trust Small Cap Growth AlphaDEX Fund
1.1%
WisdomTree BioRevolution Fund
1.08%
View more
Global X Genomics & Biotechnology ETF
Proportion5.45%
Invesco S&P SmallCap Health Care ETF
Proportion3.59%
ROBO Global Healthcare Technology & Innovation ETF
Proportion3.41%
ALPS Medical Breakthroughs ETF
Proportion2.38%
Tema Heart & Health ETF
Proportion2.18%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.89%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.77%
State Street SPDR S&P Biotech ETF
Proportion1.18%
First Trust Small Cap Growth AlphaDEX Fund
Proportion1.1%
WisdomTree BioRevolution Fund
Proportion1.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
